Details of the Drug

General Information of Drug (ID: DMSPG60)

Drug Name
TC-510
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 1/2 [1]
Ovarian cancer 2C73 Phase 1/2 [1]
Drug Type
Cell therapy
Cross-matching ID
TTD ID
DJA64B
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Ovarian tissue
The Studied Disease Ovarian cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 1.35E-02 5.44 1.92
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05451849) A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of TCR2 Therapeutics